![]() |
|
|
Vol. 281, Issue 1, 267-273, 1997
Departments of
Pharmacology (R.H.-D., L.L.B.) and
Medicine (L.L.B.)
and the
Biomedical Sciences Graduate Program (S.V., A.G.), University
of California, San Diego, La Jolla, California
In experiments on neonatal and adult rat ventricular myocytes,
endothelin (ET) binding and the effects of ET on transmembrane signaling are quasi-irreversible. The ETA receptor
antagonist BQ123 competes for binding and biochemical effects if added
simultaneously with ET; when added after ET, the antagonist prevents
neither binding nor activation of the Gi and Gq
pathways. At 4°C, at which internalization of the ligand should be
minimized, the interaction of [125I]ET is still
irreversible. After binding of radio-labeled ligand at either 4°C or
37°C, only 50% of ligand is removed by acid washing. Permeabilization of the cells with Triton X-100 fails to release irreversibly bound ligand. Binding experiments in cell membranes mimic
this irreversible binding. At 37°C, the addition of mercaptoethanol or dithiothreitol inhibits concurrent ET binding but does not cause the
dissociation of previously bound ligand or the reversal of previously
activated signaling. We conclude that ET binds irreversibly to
myocytes, that this irreversibility is reflected in the biochemical responses of the cells to ET and that the irreversibility is more complex than the formation of S---S bonds between surface receptors and
ET or internalization of bound ET. We interpret these findings and
others in the literature in light of a testable model of
ETA receptor/G protein/effector interaction in which
quasi-irreversible binding of ET to the ETA receptor occurs
before the interaction of the ligand/receptor complex with G protein
and in which irreversible binding contributes to the prolonged effects
of ET and is a prelude to refractoriness and to the slow regeneration
of free ETA receptor.
This article has been cited by other articles:
![]() |
M. Tosun, Y. Erac, C. Selli, and N. Karakaya Sarcoplasmic-endoplasmic reticulum Ca2+-ATPase inhibition prevents endothelin A receptor antagonism in rat aorta Am J Physiol Heart Circ Physiol, April 1, 2007; 292(4): H1961 - H1966. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Brighton, P. G. Szekeres, A. Wise, and G. B. Willars Signaling and Ligand Binding by Recombinant Neuromedin U Receptors: Evidence for Dual Coupling to G{alpha}q/11 and G{alpha}i and an Irreversible Ligand-Receptor Interaction Mol. Pharmacol., December 1, 2004; 66(6): 1544 - 1556. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Boivin, D. Chevalier, L. R. Villeneuve, E. Rousseau, and B. G. Allen Functional Endothelin Receptors Are Present on Nuclei in Cardiac Ventricular Myocytes J. Biol. Chem., August 1, 2003; 278(31): 29153 - 29163. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Talbodec, N. Berkane, V. Blandin, J. P. Breittmayer, E. Ferrari, C. Frelin, and P. Vigne Aspirin and Sodium Salicylate Inhibit Endothelin ETA Receptors by an Allosteric Type of Mechanism Mol. Pharmacol., April 1, 2000; 57(4): 797 - 804. [Abstract] [Full Text] |
||||
![]() |
C. P. Tiefenbacher, D. V. DeFily, and W. M. Chilian Requisite Role of Cardiac Myocytes in Coronary {alpha}1-Adrenergic Constriction Circulation, July 7, 1998; 98(1): 9 - 12. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Bhowmick, P. Narayan, and D. Puett The Endothelin Subtype A Receptor Undergoes Agonist- and Antagonist-Mediated Internalization in the Absence of Signaling Endocrinology, July 1, 1998; 139(7): 3185 - 3192. [Abstract] [Full Text] [PDF] |
||||